Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Crystal Arthritis
When would you recommend uric acid-lowering therapy for a patient with asymptomatic hyperuricemia without comorbidities but with family history of gout?
Related Questions
Do you delay pegloticase in a patient with an active gout flare?
Do you avoid hyaluronic acid injections in patients with chondrocalcinosis on imaging?
Do you routinely recommend barbotage for calcific tendinopathy of the shoulder?
Why are gout flares common in hospitalized patients undergoing diuresis but not commonly observed in cancer patients with hyperuricemia resulting from tumor lysis syndrome?
How do you approach using DMARDs for patients with CPP arthritis who have frequent flares?
Are there adverse consequences of suppressing serum urate levels too much?
Do you still consider the use of pegloticase in someone with substantial tophaceous burden despite optimal uric acid levels?
Can Milwaukee shoulder present with a large subacromial bursitis, or does it predominantly cause joint effusion/destruction?
Is there any expanded diagnostic workup that you pursue for a young female patient with gout?
Do you prefer using losartan in your patients with hypertension and gout due to its uricosuric effects?
